Understanding pancreatic exocrine insufficiency and replacement therapy in pancreatic cancer

Research output: Contribution to journalArticlepeer-review


  • S. Powell-Brett
  • N. de Liguori Carino
  • K. Roberts

Colleges, School and Institutes


Pancreatic exocrine insufficiency (PEI) is highly prevalent in patients with pancreatic cancer, and has substantial implications for quality of life and survival. Post resection, PEI is associated with increased post-operative complications, longer hospital stays and higher costs. Treatment with pancreatic enzyme replacement therapy (PERT) improves quality of life and confers significant survival advantages. Despite this many patients with pancreatic cancer do not currently receive PERT. The nutritional consequences of PEI are extensive and even more relevant in the elderly owing to age related gastrointestinal tract and pancreatic changes that predispose to malnutrition.


Original languageEnglish
JournalEuropean Journal of Surgical Oncology
Early online date8 Mar 2020
Publication statusE-pub ahead of print - 8 Mar 2020


  • pancreatic exocrine insufficiency, pancreatic cancer, nutrition, elderly